This study examined the antibiotic resistance patterns of group B streptococci (GBS) isolated from gravid women. A total of 156 vaginal and cervical isolates of GBS were examined for resistance to penicillin, ampicillin, clindamycin, cefoxitin, gentamicin, and (1, 5, 6 ) and infection in the peripartum period. Intrapartum vertical transmission and early onset GBS infection have been prevented (5) by administration of ampicillin to targeted populations thought to be at risk for infant disease (5, 16, 19, 22) .
Group B streptococci (GBS) are pathogens which have been associated with preterm labor (15, 18, 19) , premature rupture of membranes (15, 18) , and neonatal sepsis (2) . Babies born to women with rectal, vaginal, or urinary tract carriage of GBS are at risk for colonization (1, 5, 6) and infection in the peripartum period. Intrapartum vertical transmission and early onset GBS infection have been prevented (5) by administration of ampicillin to targeted populations thought to be at risk for infant disease (5, 16, 19, 22) .
However, even the most selective strategies have exposed large populations to antibiotic therapy. This renewed interest in antibiotic treatment of parturient women to prevent early onset GBS disease and an increased number of recommendations for screening and treatment of other infections such as Chlamydia trachomatis (21) during pregnancy have led to concern about the development of antibiotic resistance by GBS. This concern is supported by reports of the emergence of penicillin-tolerant strains of GBS (12) , penicillin treatment failures in infected neonates (12) , and the observation of strains with multiple beta-lactam resistance phenotypes in bovine populations exposed to heavy antibiotic use (4) . Plasmid-mediated drug resistance has also been shown to occur in GBS and may facilitate the development of multidrug resistance (9) .
Most previous studies of GBS antibiotic susceptibility patterns were performed at a time when antibiotic use in pregnancy was less widespread. This study was conducted to determine whether changes in GBS antibiotic susceptibility have occurred in the current era of more liberal use of antibiotics among pregnant patients. Antibiotic patterns of susceptibility of GBS isolated from an inner city population of parturient women were determined for penicillin, ampicillin, gentamicin, clindamycin, cefoxitin, and erythromycin. GBS strains were also assayed for penicillinase production. MATERIALS (11) . Strains resistant to gentamicin alone were not tested for MIC. Penicillinase production was assayed by the chromagen disk method (Cefinase; BBL Laboratories) and penicil- linase-producing Staphylococcus aureus as a positive control.
RESULTS
Among 1,378 women screened antenatally, 25% were colonized with GBS and 18% were colonized at the time of delivery. The percentages of strains resistant, intermediate, or susceptible to each antibiotic are presented in Table 1 . All 156 strains tested were susceptible to penicillin and to ampicillin. No strain produced penicillinase. Of the remaining antibiotics tested, gentamicin exhibited the least activity against GBS, with 91% of the strains resistant. Notably, 9.0, 9.5, and 15.3% of the isolates exhibited either resistance or an intermediate response to erythromycin, clindamycin, and cefoxitin, respectively. Thirty strains (19%) were not susceptible to two antibiotics. Sixteen strains (10%) were not susceptible to three antibiotics, and eight (5%) were susceptible only to the penicillins.
DISCUSSION
The choice of antibiotic to be used for eradication of GBS colonization of the vagina presents a therapeutic dilemma. While penicillins remain the drug of choice for systemic infection caused by GBS, treatment failure rates of up to 50% (6) have been reported when penicillin or ampicillin is used to eradicate GBS from the lower reproductive tract of women.
Our study confirms earlier reports (3, 17) of 100% in vitro susceptibility of GBS to penicillin and ampicillin. Efforts to induce penicillin tolerance by the methods of Kim et al. (12) and Horn et al. (10) were ineffective. Furthermore, no strain of GBS was capable of penicillinase production.
In vitro susceptibility, while important, is not the only factor determining treatment efficacy. Tissue levels of penicillin, vaginal pH, and concomitant colonization of the vagina with penicillinase-producing organisms are among the factors influencing treatment failure rates. Alternatively, erythromycin has been used in the treatment of GBS colonization (14; J. A. Regan, unpublished data). In our experience, treatment failures of only 10 to 15% have been encountered after 10 to 14 days of treatment. This efficacy rate coupled with the wider spectrum of activity of erythromycin against lower reproductive tract pathogens, its safety in pregnancy, and its low incidence of gastrointestinal side effects when administered in the base form make it a logical choice for treatment of GBS.
Of concern in this work is the level of tolerance for erythromycin exhibited among the 156 isolates studied. Of note, five isolates were resistant to erythromycin while nine demonstrated an intermediate susceptibility. The rate of susceptibility to erythromycin is lower than we have previously reported in a study conducted 2 years earlier (8) and that of other earlier reports (17) .
In recent years, the use of erythromycin in the treatment of lower reproductive tract infections such as chlamydia (21) has become widespread. It is possible that resistance to erythromycin is being induced in GBS by prior exposure to erythromycin. We are currently addressing the issue of drug-induced resistance in GBS isolates after prolonged exposure to erythromycin in a 6-to 11-week treatment regimen.
Of interest is our finding of 91% resistance of GBS isolates to gentamicin in light of a controversy which has existed concerning the use of gentamicin in selective broth medium as advocated by Baker et al. (1) . This medium contains 8 ,ug of gentamicin sulfate per ml. Baker et al. claimed this was not inhibitory to GBS on the basis of their study of the susceptibility of 244 GBS isolates to gentamicin, in which the median MIC was 25 ,ug/mi and the range was 12.5 to 100 ,ug/ml (3). Our finding of 2% susceptible and 7% intermediately susceptible isolates supports the position of Gray et al. (7), who reported the not infrequent occurrence of gentamicin-resistant strains.
Clindamycin and cefoxitin were selected for study in this work because of their widespread use in treatment of obstetrical patients with postpartum endometritis and the widely held clinical opinion that they provide good coverage against GBS. Earlier susceptibility studies indicated greater-than-95% susceptibility to clindamycin and cefoxitin, while in this study only 90 and 86% of strains were susceptible to clindamycin and cefoxitin, respectively.
Multiple antibiotic resistance patterns are documented in this study, with 16 strains exhibiting resistance or an intermediate susceptibility to two or more antibiotics other than gentamicin.
In many laboratories the susceptibilities of GBS are not tested since isolates of GBS, as reconfirmed in this study, are uniformly susceptible to penicillins in vitro. High in vivo treatment failure rates have led to use of other antibiotics including erythromycin, clindamycin, and cefoxitin for GBS coverage. We suggest that the levels of antibiotic tolerance exhibited by GBS isolates in this study argue in favor of routine susceptibility testing of clinical isolates. This study coupled with significant in vivo penicillin treatment failure rates provide evidence of potential nonefficacious treatment regimen choices even when two-drug combinations are used.
To update what is known of GBS antibiotic susceptibility patterns in an era of widespread antibiotic use during pregnancy, we studied the susceptibilities of 156 GBS isolates to penicillin, ampicillin, clindamycin, cefoxitin, gentamicin, and erythromycin and investigated penicillinase production. We found 100% susceptibility to the penicillins and 91% resistance to gentamicin. Patterns of susceptibility to erythromycin, clindamycin, and cefoxitin revealed resistance or intermediate susceptibility at higher rates than have been previously reported.
Since factors other than in vitro susceptibility are operational in the efficacy of penicillin in the treatment of the GBS-colonized gravida, the selection of alternative antibiotic treatment is of considerable clinical significance. In light of our findings of higher and multiple-resistance patterns of GBS to erythromycin, cefoxitin, and clindamycin, we recommend that routine reporting of GBS susceptibilities be adopted to help guide the clinician in the choice of antibiotic therapy.
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